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Introduction
The potassium channel–interacting protein (KCNIP4, also known 
as KChIP4; NCBI Protein database accession no. NP_079497.2) 
is a physical interactor of the  subunit of Kv4, a neuronal   
A-type voltage-dependent potassium channel (Kitagawa et al., 
2007). By the means of such an interaction, it participates in the 
regulation of the A-type current needed for the generation of 
slow repetitive firing in neurons, thus strongly contributing to 
the molecular properties of potassium channels (Etcheberrigaray 
et al., 1993; Shibata et al., 2003; Rhodes et al., 2004). Previ-
ous work demonstrated that KCNIP4 also interacts in vivo and 
in HEK293 cells with presenilins (PSs), the key components 
of the -secretase complex that processes the amyloid precur-
sor protein (APP) to generate the A fragments involved in 
Alzheimer’s disease (AD; Morohashi et al., 2002; Parks and 
Curtis,  2007).  A  set  of  possible  KCNIP4  alternative  splicing 
variants with peculiar biochemical and biophysical properties 
may account for a complex pattern of splice form–dependent 
protein–protein interactions (Deng et al., 2005; Pruunsild and   
Timmusk, 2005). In this context, the canonical splice variant 1 
(also referred to as KChIP41b and hereafter referred to as Var I) 
is widely expressed in all of the brain cell components tested, 
whereas the alternatively spliced KCNIP4 variant 4 (also referred 
to as KChIP4a and hereafter referred to as Var IV; Fig. S1, A and B)   
is specifically expressed in the globus pallidus and basal fore-
brain neurons (Baranauskas, 2004; Trimmer and Rhodes, 2004). 
Notably, these alternatively spliced cell type–specific KCNIP4 
variants also account for changes of the A-type current among 
different  cell  types  (Patel  et  al.,  2002;  Boland  et  al.,  2003; 
Decher et al., 2004). In fact, the fast inactivation of the A-type 
current physiologically associated with Kv4 channels, which 
takes place when KCNIP4 is canonically spliced to Var I, is rapidly 
A
lternative  splicing  generates  protein  isoforms 
that are conditionally or differentially expressed   
in specific tissues. The discovery of factors that 
control alternative splicing might clarify the molecular basis 
of biological and pathological processes. We found that 
IL1-dependent up-regulation of 38A, a small ribonu-
cleic acid (RNA) polymerase III–transcribed RNA, drives 
the synthesis of an alternatively spliced form of the potas-
sium channel–interacting protein (KCNIP4). The alternative 
KCNIP4  isoform  cannot  interact  with  the  -secretase 
complex, resulting in modification of -secretase activity, 
amyloid precursor protein processing, and increased se-
cretion of -amyloid enriched in the more toxic A x-42 
species. Notably, synthesis of the variant KCNIP4 isoform 
is also detrimental to brain physiology, as it results in the 
concomitant  blockade  of  the  fast  kinetics  of  potassium 
channels. This alternative splicing shift is observed at high 
frequency in tissue samples from Alzheimer’s disease pa-
tients, suggesting that RNA polymerase III cogenes may 
be upstream determinants of alternative splicing that sig-
nificantly contribute to homeostasis and pathogenesis in 
the brain.
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transformed in a slowly inactivated potassium current when an 
alternative splicing event leads to the synthesis of KCNIP4 
Var IV as a result of reduced trafficking of Kv4 channels to the 
surface membrane (Holmqvist et al., 2002; Schwenk et al., 2008). 
This condition is associated with an impairment of the electro-
physiological properties of the cell, affecting the excitatory or 
the inhibitory back-propagating action potentials that ultimately 
participate in associative events such as long-term potentiation 
(LTP) and long-term depression. In addition, possible cis- or 
trans-acting  factors  that  select  the  alternative  splicing  forms 
could drive the cell to an altered synaptic behavior based on the 
impairment of its excitatory properties. Moreover, the notion 
that a perturbation of LTP might contribute to the phenotypic 
manifestations of neurodegeneration, together with the fact that 
the other KCNIP4 partners (the PSs) are deeply involved in the 
etiology of AD, strongly suggests a possible involvement of 
KCNIP4 alternative splicing in neurodegenerations.
This work originates from our recent identification of a set 
of 30 RNA polymerase III (PolIII)–dependent noncoding RNAs 
(ncRNAs) that we proposed as novel gene expression regula-
tory elements acting by the generation of specific PolIII/PolII 
cogene/gene pairs (Dieci et al., 2007; Pagano et al., 2007). 
Interestingly, one of these transcripts (hereafter referred to as 38A) 
maps within KCNIP4 gene intron 1, a region involved in the   
alternative splicing events leading to Var IV of KCNIP4 (Fig. S1, 
A and B). Considering the antisense configuration of 38A with 
respect to KCNIP4 intron 1, we hypothesized that KCNIP4 
pre-mRNA and 38A ncRNA might form a sense/antisense RNA 
pair, thus masking KCNIP4 canonical splice sites and leading 
to the synthesis of alternatively spliced forms possibly asso-
ciated with peculiar pathological conditions. Here, we report 
evidence that 38A is indeed the first player of a novel molecu-
lar pathway that leads to the altered amyloid production asso-
ciated with AD etiology as well as with the perturbation of 
the A-type current that ultimately leads to the impairment of 
cellular excitatory properties. We further report that inflamma-
tory stimuli trigger 38A-dependent alternative splicing, thus 
providing a molecular link between inflammation and the eti-
ology of neurodegeneration, and we describe some allelic vari-
ants of the 38A promoter that might contribute to enhancing the 
genetic susceptibility of certain individuals to the activation of 
this pathological process.
Results
38A ncRNA is transcribed by RNA PolIII
The putative 38A ncRNA gene was identified in a previous com-
putational screen for novel human PolIII target genes (Pagano 
et al., 2007). First, we verified 38A activity as a PolIII template 
Figure 1.  In vitro transcription analysis of 38A. (A) Transcription products 
of 38A or empty vector (pNEB) were either radiolabeled during synthesis 
and directly visualized (lanes 1 and 2) or subjected to primer extension 
analysis (lanes 3–6; lane 3, no DNA; lane 5, no reverse transcription). 
In lane 6, the main primer extension product is indicated by a red arrow-
head. Lanes 7–10 are sequencing reactions primed with the same oligo-
nucleotide. The sequence of the 38A transcription unit is reported (PSE, TATA,   
and terminator in red, transcription start site in blue, and transcribed region 
underlined). (B) In vitro transcription and primer extension analysis with the 
human 7SK gene (lanes 1 and 10), promoterless 7SK (lanes 3 and 9), and 
the 7SK transcribed region fused with 38A promoter (lanes 2 and 8) as tem-
plates. The sequence of the hybrid transcription unit is reported (PSE, TATA, 
and terminator sequences in red and the 38A-derived upstream sequence 
in italic). The red arrowhead indicates the position of the most abundant 
primer extension product. (C) ChIP analysis in SHSY5Y-cultured cells using 
anti-PolIII, anti-SNAPc, or anti-Brf2 antibodies. Association with the GAPDH 
control gene and either the U6 gene (lanes 1–4) or the 38A locus (lanes 
5–8) was assessed by PCR on both input (lanes 4 and 8) and immuno-
precipitated DNA samples interrogated with both target-specific and control 
primer pairs. Target enrichment in the immunoprecipitated DNA is reported 
below the lanes. (A and B) Black lines indicate that intervening lanes have 
been spliced out. Molecular mass is indicated in base pairs..
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natural promoter) and measured changes in the levels of Var I 
and Var IV mRNAs by real-time RT-PCR. As shown in Fig. 2 A, 
48 h after transfection, a remarkable alteration of Var IV versus 
Var I ratio was detected (21.1 vs. 1) in SHSY5Y cells as a con-
sequence of an increased generation of Var IV and a decreased 
synthesis of Var I. The same result was obtained with SKNBE 
cells, although this cell type transcribes 38A less efficiently. 
Overexpression of 17A, a distinct PolIII-transcribed regulatory 
RNA that maps in an unrelated locus, did not exert any effect on 
KCNIP4 pre-mRNA maturation. Altogether, these results indi-
cate that 38A overexpression is sufficient to drive the alternative 
splicing shift of KCNIP4 mRNAs, promoting the synthesis of the 
Var IV isoform. With respect to Var I, this isoform encompasses 
a KIS domain in its N terminus that enables it to inhibit the fast 
kinetics of inactivation of A-type voltage-dependent potassium 
channels (Holmqvist et al., 2002).
The 38A-driven alternative splicing was also evidenced 
at the protein level. Taking advantage of a KCNIP4-specific 
antiserum raised against an internal region of the human protein 
(hereafter referred to as KChIP4-L14), we detected a signifi-
cant increase of KCNIP4 signal at 25 kD and a concomitant 
decrease of the signal at 28 kD. The relative abundance of the two 
KCNIP4 forms was quantified as a Var IV versus Var I protein 
ratio, and it was increased 2.2-fold in p38A-transfected cells   
as compared with those transfected with pMock (Fig. 2 B).   
in vitro using a HeLa cell nuclear extract. As shown in Fig. 1 A, 
in vitro transcription of a plasmid-borne 38A construct contain-
ing the upstream proximal sequence element (PSE) and the TATA 
box, followed by the putative 352-bp transcribed region, produced 
RNAs of different sizes (lane 2); primer extension analysis (lanes 
3–10) revealed that transcription initiated 30 bp downstream of 
the TATA box. As further shown in Fig. 1 B, the 38A promoter 
region was also found to be active in directing faithful 7SK gene 
transcription in fusion constructs. The association of the 38A 
transcription unit with PolIII-specific transcription proteins was 
tested in vivo by chromatin immunoprecipitation (ChIP) analy-
sis. Fig. 1 C shows the results of a ChIP analysis conducted on 
SHSY5Y-cultured cells using anti-Brf2 (a TFIIIB component), 
anti-SNAP43 (a SNAP-C component), and anti-RPC39 (a PolIII 
subunit) antibodies. 38A was found to be specifically enriched in 
all the immunoprecipitations.
38A transcription drives KCNIP4 
alternative splicing
We then tested whether the overexpression of 38A causes a gene-
specific alternative splicing shift of KCNIP4. To this end, we 
focused on the two physiologically relevant splice variants Var I   
and Var IV. We transiently transfected SHSY5Y and SKNBE 
neuroblastoma cells (Biedler et al., 1973; Biedler and Spengler, 
1976) with a construct expressing 38A transcript (driven by its 
Figure  2.  ncRNA-induced  alternative  splicing 
analysis.  (A)  Real-time  RT-PCR  detection  of 
KCNIP4  splice  variant  synthesis  in  SHSY5Y 
and/or in SKNBE cells transiently transfected 
with either 38A or 17A (a noncorrelated PolIII-
transcribed ncRNA used as a negative control) 
expression plasmids. Altogether, these results 
indicate  that  each  ncRNA  specifically  influ-
ences  the  splicing  of  its  corresponding  pro-
tein-coding gene. (B) Western blotting analysis 
of the 38A-dependent alternative splicing of 
KCNIP4. In pMock-transfected cells, the rela-
tive abundance of the 250-residue-long form 
of KCNIP4 (Var I, striped bars) is predominant 
with respect to the alternatively spliced 229-
residue-long form (Var IV, shaded bars) that, in 
turn, is the main KCNIP4 form synthesized by   
p38A-transfected cells. Quantitative bars and the   
correspondent error bars (SD) are referred to the 
mean of three independent experimental determi-
nations (A and B). The p38A-dependent change   
of Var IV versus Var I protein form ratio is quanti-
tatively reported (inset in B). (C and D) Immuno-
fluorescence detection of KCNIP4 alternative 
splicing. Antibodies raised against the KCNIP4 
N-terminal fragment of the protein form I show 
a clearly detectable signal in GFP-expressing 
cells only in the absence of a concomitant 38A 
overexpression (arrows in C); on the contrary, 
the signal is absent or very weak in cells trans-
fected with a construct coexpressing 38A and 
GFP (arrows in D). Untransfected cells, which 
do not express GFP and 38A, are positive for 
KCNIP4 (arrowheads in D).JCB • VOLUME 193 • NUMBER 5 • 2011   854
the activation of 38A expression could be associated with an 
altered function/state of synapses, as it may occur in neurologi-
cal disorders.
38A-driven alternative splicing abolishes 
KCNIP4–PS2 interaction
Because it has been previously reported that KCNIP4 interacts 
with PS2 (NCBI Protein accession no. P49810; Herreman 
et al., 2000; Morohashi et al., 2002; Bentahir et al., 2006), we 
tested the two alternative KCNIP4 protein forms for their pos-
sible interaction with PS2. 48 h after transfection of SHSY5Y 
cells with p38A or pMock constructs, we immunoprecipitated 
KCNIP4 by the KChIP4 L-14 IgGs and analyzed the immuno-
precipitation  products  by  SDS-PAGE  coupled  with  Western 
blotting  challenged  by  the  anti-PS2  antibody  (PS2  H-76).  In 
pMock-transfected  cells,  PS2  coimmunoprecipitates  with 
KCNIP4, confirming the previously reported physical interaction 
(Morohashi et al., 2002). Interestingly, the PS2 signal was signifi-
cantly decreased in p38A-transfected cells, where KCNIP4 Var IV 
is predominantly synthesized and recognized by the same anti-
serum; as the control, another component of the -secretase com-
plex (PS1) is not coimmunoprecipitated with KCNIP4 (Fig. 4 A).
When the experiment was repeated in the presence of 
the PolIII-specific inhibitor ML-60218, PS2 was found to co-
immunoprecipitate with KCNIP4 in both pMock-transfected and 
p38A-transfected cells (Fig. 4 B). The rescue of KCNIP4–PS2 
protein–protein  interaction  by  PolIII  inhibition  and  the  lack 
of  coimmunoprecipitation  of  KCNIP4  with  another  member 
of the -secretase complex (PS1), together with the observa-
tion that 38A expression does not affect the level of synthesis   
of PS2 and/or PS1 (Fig. 4 C), further demonstrates that the PolIII-
dependent synthesis of 38A specifically prevents KCNIP4–PS2 
protein–protein interaction. Furthermore, it suggests that this phe-
nomenon might affect the role played by PS2 in the -secretase 
complex and, possibly, in APP proteolytic processing. We next 
tried  to  corroborate  this  finding  by  the  immunofluorescence 
analysis of KCNIP4 Var IV subcellular localization. To this aim, 
we raised a Var IV–specific antiserum (hereafter referred to as 
-KCNIP4 Var IV) that recognizes a Var IV–specific N-terminal   
portion (KLLEQFGLIEAGLEC). This antiserum produced a   
strong protein signal in p38A-transfected cells and a very weak 
signal in cells permanently transfected with the pMock con-
struct, confirming its specific recognition of the alternative 
KCNIP4 Var IV (Fig. 4, D and D). We next took advantage of 
the -KCNIP4 Var I antibody to evidence the colocalization of 
KCNIP4 Var I and PS2 in SHSY5Y-pMock cells and the lack 
of it in SHSY5Y 38A–overexpressing cells, coinciding with the 
data obtained by coimmunoprecipitation (Fig. 4, E and E). The 
same analysis was finally repeated using the -KCNIP4 Var IV 
antiserum, showing again that this isoform does not colocalize 
with PS2 (Fig. 4, F and F). Altogether, the aforementioned re-
sults indicate that the synthesis of KCNIP4 Var IV promoted 
by 38A expression prevents its physical interaction with PS2, 
suggesting a possible functional relevance of this alternative 
splicing shift.
Besides  the  marked  effects  driven  by  the  synthesis  of 
KCNIP4 Var IV, it was previously found by others that KChIP3 
To verify the PolIII dependency of this phenomenon, we prevented 
the expression of 38A by a treatment with 20 µM ML-60218, an 
RNA PolIII–specific inhibitor (Fig. S2; Wu et al., 2003).
Alternative  splicing  control  by  38A  is  further  supported 
by  the  results  of  immunofluorescence  microscopy  analysis. 
Using a polyclonal antibody raised against the N terminus of 
KCNIP4 Var I (KChIP4 N-14), we observed a marked immuno-
fluorescence signal in pMock-transfected SHSY5Y cells; in 
this condition, 38A is not overexpressed, and the canonical Var I is 
predominantly synthesized (Fig. 2 C). In contrast, a strongly de-
creased signal was detected in cells overexpressing 38A where 
the alternative protein form IV (harboring a different N-terminal 
portion and not recognized by the same IgGs) is predominant, 
whereas the synthesis of KCNIP4 Var I was strongly decreased 
(Fig. 2 D). Altogether, the aforementioned results support the 
model of 38A as a key supervisor of the synthesis of function-
ally different KCNIP4 protein isoforms and bring to light a 
novel, unexpected role of PolIII-transcribed ncRNAs in gene 
expression regulation.
38A expression prevents the fast 
inactivation of A-type K
+ channels
KCNIP4 Var IV is known to influence the cell excitatory prop-
erties by abolishing the fast inactivation of A-type potassium 
channels on which rapid neuron firing depends (Baranauskas, 
2004). Such alteration has been associated with neurodegen-
erative processes (Angulo et al., 2004; Waters et al., 2006). To 
test whether 38A expression can perturb the excitatory proper-
ties of synapses in neurons, we first searched for the proper 
cell culture system for the determination of the A-type current. 
SKNBE-NDM29 cells (a SKNBE clone with characteristics of 
neurons; Castelnuovo et al., 2010) turned out to be a system in 
which this current is well detected. We transfected these cells 
with plasmids harboring 38A under the control of its natural 
promoter (pEGFP-N1–38A) and/or without insert (pEGFP-N1). 
48 h after transfection, we measured the inactivation time in 
a large panel of cells for each sample. Fig. 3 shows the out-
ward potassium current elicited in control (Fig. 3 A) and in 
38A cells (Fig. 3 B) by depolarization steps from a 80-mV 
holding potential. The inactivation time course of this current 
could be described by a single exponential curve. In 75% of 
38A cells, the time constant of the inactivating potassium cur-
rent was increased. The time constant of the current elicited 
by depolarizing steps to 60 mV was found to be close to 1,130 ms   
in the 38A cells as opposed to the time constant (580 ms) 
of the control cell current. Considering the transfection effi-
ciency (70–80%), virtually all of the 38A-expressing cells are 
affected. When the same cells were transfected with constructs 
expressing the alternatively spliced KCNIP4 Var IV and/or the 
N-terminal KIS domain specifically coded by Var IV, both con-
ditions produced the inactivation of potassium current, reca-
pitulating the same effect elicited by 38A overexpression (Fig. 3, 
C–F). Altogether, these data demonstrate that 38A can abolish 
the fast inactivation of the A-type voltage-dependent potas-
sium channels, thus affecting the transient component of their 
A-type current. Considering that this phenomenon significantly 
affects the excitatory potentiality of the cell, we concluded that 855 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
properties of KV4 channels. We thus tested whether the stable 
overexpression of 38A in SHSY5Y cells and the consequent 
synthesis of KCNIP4 Var IV perturb the interaction of Calsenilin 
with PS1. To this aim, we measured by Western blotting possible 
isoform (namely Calsenilin) also plays a fundamental role in the 
-secretase protein complex–dependent cleavage of the A pre-
cursor (Buxbaum et al., 1998). Indeed, KChIP3 is a physical in-
teractor of PS1 and participates in the regulation of the electrical 
Figure 3.  Effects of 38A expression on A-type potassium current. (A–F) Outward potassium current in pMock-transfected control cells (A, C, and E), in 
38A-overexpressing cells (B), in pETmKChIP4a (D), and in pMaLmKIS-transfected cells (F). Step depolarizations were delivered with 20-mV increments. The 
holding potential was 80 mV. The transient overexpression of the recombinant KCNIP4 Var IV is reported in D as resulting from real-time RT-PCR analysis. 
The overexpression of the recombinant N-terminal (KIS) domain is reported in F, as resulting from real-time RT-PCR analysis. Error bars are SD.JCB • VOLUME 193 • NUMBER 5 • 2011   856
Figure 4.  Lack of KCNIP4–PS2 protein–protein interaction in 38A-overexpressing cells. (A) PS2 is detected by anti-PS2 IgGs in samples immunoprecipi-
tated (IP) with anti-KCNIP4 in pMock-transfected cells, whereas PS2-KCNIP4 coimmunoprecipitation is prevented in 38A-overexpressing cells (P = 0.023, 
as the averaged result of five experiments). In the same samples, the lack of immunoprecipitation of KCNIP4 with a different component of the -secretase 
complex (PS1) is shown. (B) The 38A-dependent impairment of PS2/KCNIP4 protein–protein interaction is prevented by the treatment of cells with the 
PolIII inhibitor ML-60218. (C) Input sample demonstrating that the amount of PS2 and PS1 in the protein sample is not affected by 38A overexpression.   857 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
AD (Fig. 5 C). To further demonstrate the PolIII dependency 
(and the association with 38A) of the perturbation of A pro-
cessing, a parallel experiment was performed in the presence 
of 20 µM ML-60218; in this condition, the increment of both 
A x-42 and A x-40 was prevented, confirming the role of 38A 
PolIII–dependent expression in the impairment of A peptide 
production (Fig. 5 C). In this experiment, the specific inhibi-
tion of PolIII was confirmed, evidencing a decreased synthesis 
of PolIII-transcribed RNAs (5S ribosomal RNA [rRNA], 7SK 
RNA, and 38A RNA) and a concomitant unaffected expression 
of PolII-dependent genes (cMyc and glyceraldehyde 3 phos-
phate dehydrogenase [GAPDH]; Fig. 5 D). Next, to discrimi-
nate whether the altered secretion of A in p38A-SHSY5Y 
cells has to be ascribed to a different level of APP process-
ing or rather to the modulation of APP and/or PS2 synthesis, 
we measured their amount in the same experimental settings. 
Results showed that the levels of both APP and PS2 are not 
affected by the overexpression of 38A, either in the absence 
or in the presence of ML-60218, demonstrating that the per-
turbation of A promoted by 38A is specifically determined 
by the increase of APP processing (Fig. 5 E). This point was 
also confirmed by measuring A secretion in 38A-transfected 
APP-overexpressing  HEK293  cells  that  stably  overexpress 
APP. Indeed, although the amount of A secreted is consider-
ably higher in these cells, the effects of 38A overexpression on 
APP processing recapitulate those obtained in SHSY5Y cells 
(Fig. S4 F).
We took advantage of a KCNIP4 Var IV–specific silenc-
ing RNA (hereafter referred to as siVar IV) to test the possible 
rescue of the 38A/KCNIP4 Var IV–dependent impairment of 
A secretion. To this aim, we transiently cotransfected p38A 
expressing  together  with  siVar  IV  plasmid  (or  a  scrambled 
siRNA-expressing plasmid as a control) and measured by real-
time RT-PCR the amount of KCNIP4 Var I and Var IV mRNAs 
and the consequent variations of the secreted amyloid. Despite 
the overexpression of 38A, cells in which the Var IV was si-
lenced expressed a significantly increased amount of the ca-
nonical Var I (up to a 7.84-fold increase with respect to pMock 
cells) and a decreased amount of Var IV (up to 0.35-fold of their 
original level; Fig. 5 F). In this condition, the secretion of A 
x-40 and A x-42 in the medium was reduced by 20 and 62%, 
respectively. As a consequence, the same samples exhibited a 
27% reduced secretion of total amyloid and a 36% reduced A 
x-42/A x-40 ratio (Fig. 5 G). Thus, considering that the in-
creased processing of APP induced by 38A can be reverted by 
the silencing of the alternative isoform IV, we hypothesized that 
38A expression affects A secretion by promoting the synthesis 
of an alternative KCNIP4 protein form. Indeed, the same effect 
on A secretion driven by 38A overexpression can be replicated 
alterations of PS1 and/or KChIP3 in 38A-overexpressing cells. 
The statistical analysis of the results showed that the increased 
expression of 38A does not significantly alter the amount of 
this protein in the cell (unpaired Student’s t test: KChIP3 varia-
tion, P = 0.08; Fig. 4 G). Next, we investigated by immuno-
fluorescence possible changes of the subcellular localization 
of  KChIP3  and/or  PSs  in  38A-overexpressing  cells.  Results 
showed a distinguishable overlapping of –anti-PS1 (-PS1) 
and  –anti-KChIP3  (-KChIP3)  both  in  pMock-treated  and 
38A-overexpressing cells, confirming that KChIP3 colocalizes   
with PS1 and that their interaction is not affected by the synthe-
sis of KCNIP4 Var IV (Fig. 4, H and H). Taking advantage of a 
PS2-specific antiserum, we also found that the overexpression of 
38A does not affect the subcellular localization of PS2 (Fig. 4, 
I and I). Therefore, our data do not support possible changes 
of KChIP3 interaction with PSs driven by the increased expres-
sion of 38A.
The expression of 38A specifically  
enhances the secretion of the  
neurotoxic A x-42 species
In light of the findings in the previous section and considering 
that the proteolytic processing of APP plays a central role in 
AD etiology through the formation of neurotoxic A peptides 
(Johnson et al., 1990; Selkoe, 1990; Hardy and Selkoe, 2002;   
St George-Hyslop and Petit, 2005; Haass and Selkoe, 2007), we 
decided to investigate whether the selective overexpression of 
38A ncRNA would affect the formation of A x-42 and/or A 
x-40 species by measuring their relative amount in the medium 
of 38A-overexpressing SHSY5Y cells. As A processing might 
be altered by the transfection procedure, we first generated p38A 
and pMock permanently transfected cell lines (hereafter re-
ferred to as p38A-SHSY5Y and pMock-SHSY5Y, respectively). 
p38A-SHSY5Y cells, harboring extra copies of the 38A tran-
scription unit with its natural PolIII type 3 promoter, exhibit a 
moderate overexpression of 38A ncRNA and, as a consequence, 
a 3.1-fold increased KCNIP4 Var IV/Var I ratio (Fig. 5, A and B). 
Culture media conditioned for 48 h with p38A-SHSY5Y and/or 
pMock-SHSY5Y cells were tested for their A peptide com-
position, showing that 38A significantly enhances the levels of 
A x-42 (up to 1.91-fold with respect to the pMock-transfected 
control), whereas its effect on the secretion of the more soluble 
A x-40 peptide is more modest (up to 1.4-fold with respect 
to the pMock-transfected control). These results indicate that 
the transcription of 38A and the concomitant synthesis of 
KCNIP4 Var IV change both quantitatively and qualitatively 
the A secretion, leading to an increased amount of the total 
A and, notably, to a concomitant variation of the A x-42/A 
x-40 ratio that could account for the altered ratio observed in 
(D) Immunofluorescence detection of KCNIP4 Var I and Var IV by splice variant–specific antibodies in pMock-transfected cells (M) and in 38A-overexpressing 
cells (38A). Bars, 100 µm. (E) KCNIP4 Var I and PS2 signals in 38A-overexpressing cells. Bars, 100 µm. (F) The KCNIP4 Var IV–specific antiserum does 
not evidence a colocalization of KCNIP4 and PS2. Bars, 100 µm. (G) Western blot quantitative analysis of the PS1 and KChIP3 amount in Mock (M) and 
38A-overexpressing (38A) cells. (H) Immunofluorescence detection of PS1 and KChIP3 in Mock (M) and 38A-overexpressing (38A) cells. -PS1, –anti-
PS1; -KChIP3, –anti-KChIP3. (I) Immunofluorescence detection of PS2 and KChIP3 in Mock (M) and 38A-overexpressing (38A) cells. Bars, 100 µm. The 
quantification of fluorescence signals shown in D–F, H, and I is reported in the corresponding histograms D–F, H, and I. The error bars (referred to the 
mean of 10 microscope fields) were not relevant enough to be visible in the graphs. -PS2, –anti-PS2.
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in cells that do not overexpress 38A by the transient overexpres-
sion of recombinant KCNIP4 Var IV (Fig. S3), thus suggesting 
a specific mechanism.
Altogether, the aforementioned results demonstrate that 
the overexpression of 38A leads to an impaired A production 
Figure 5.  38A-induced perturbation of A secretion. (A) A schematic view of p38A and pMock plasmid constructs used to generate p38A-SHSY5Y and 
pMock-SHSY5Y permanently transfected cell lines. (B) Real-time RT-PCR quantitative determination of 38A expression and KCNIP4 splice variant ratio in 
p38A-SHSY5Y and pMock-SHSY5Y permanently transfected cell lines. (C) Increased -amyloid secretion and perturbation of the A x-42/A x-40 ratio 
in 38A-overexpressing SHSY5Y cells. X axis, transfected plasmids; y axis, quantitative determination of A (picograms/milliliter) secreted in the medium 
48 h after medium replacement as determined by sandwich ELISA. The resulting A x-42/A x-40 ratio is reported. Striped bars, samples treated with   
ML-60218 PolIII-specific inhibitor; shaded bars, untreated cell samples. (D) A demonstration that PolIII transcription is specifically inhibited in ML-60218-
treated cells, whereas it does not affect PolII activity. 5S rRNA, 7SK RNA, 38A, and c-Myc transcript abundancies were detected by real-time RT-PCR 
in cells treated with ML-60218 and in untreated controls used as described in A. (E) Quantitative Western blotting analysis of APP and PS2 synthesis in 
pMock- and/or p38A-transfected cells in ML-60218–treated and –untreated conditions. All of the determinations were normalized to -tubulin detections. 
(F and G) Suppression of the biological phenotype driven by the coexpression of 38A and KCNIP4 Var IV–specific silencing plasmid in SHSY5Y cells. 
Three independent determinations of Var IV decrease and the concomitant increase of Var I expression are shown together with the determinations of A 
secretion in siVar IV silenced (+) with respect to cells transfected with a scrambled siRNA (). The error bars were not relevant enough to be visible in the 
graphs; additional repetitions of the same experiment gave similar results (not depicted).
enhancing the secretion of the A x-42 toxic isoform to the 
detriment of the more soluble A x-40 isoform. Therefore, this 
cascade of reactions, triggered by the expression of a PolIII-
dependent ncRNA, ultimately leads to the generation of a more 
neurotoxic composition of the secreted amyloid.859 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
AD cerebral cortices show a high level of 
38A expression
As AD, the most common neurodegenerative disorder, is char-
acterized by an aberrant A secretion, we hypothesized a pos-
sible overexpression of 38A in AD cases where it would play 
an active role in the onset and/or maintenance of pathological 
manifestations. First, we measured by quantitative real-time 
RT-PCR the levels of 38A RNA in postmortem cerebral cortex 
samples obtained from 17 AD patients and 10 non-AD con-
trol (nADc) individuals (Table S1). Results evidenced that AD 
cases tend to overexpress 38A (10.45-fold on average with re-
spect to the nADc individuals), thus correlating the synthesis 
of this ncRNA with the AD phenotype. At present, we are not 
able to determine with statistic significance whether there is a 
correlation between 38A increment and a specific clinical or 
pathological marker. To date, we can only confirm that there is 
a significant positive correlation between expression of 38A and 
AD and a negative correlation with non-AD cases. This general 
conclusion is reinforced by inspection of some cases that might 
represent exceptions: (a) controls with higher levels of 38A are 
case 5, characterized by severe chronic obstructive pulmonary 
disease and likely hypoxic cerebral damage, and case 963, who 
was a cognitively normal subject but with a high load of angi-
opathy and a Braak stage III amyloid status; (b) the AD patient 
with the lowest 38A level is case 124, who is a familial AD case 
carrying mutated PS1 and in which PS1 loss/gain of function 
might exert a predominant role in comparison to 38A (Fig. 7 A). 
The unaltered transcription of the PolIII-transcribed 5S rRNA 
in the aforementioned samples indicated that the phenomenon 
is caused by the specific overexpression of 38A rather than a 
general increase of PolIII activity (unpublished data).
To confirm ex vivo that the overexpression of 38A in AD 
cases leads to the synthesis of KCNIP4 Var IV, we measured the 
relative amount of KCNIP4 Var I and Var IV in cortical ex-
tracts from AD and nADc individuals. Results confirmed that 
the overexpression of 38A in AD cases is associated with the 
alternative splicing shift of KCNIP4 that leads to the enrich-
ment of Var IV to the detriment of the canonically expressed 
The enhanced synthesis of 38A affects A 
secretion, altering APP processing
To validate the hypothesis that 38A affects A secretion by 
altering APP processing, we tested the possible change of the 
C-terminal fragments profile generated by APP cleavage in 
38A-overexpressing cells. To better detect these small C-terminal 
fragments in SDS-PAGE, we transiently transfected the 38A-
expressing plasmid in HEK293-APP cells that harbor extra 
copies of the APP transcription unit. As shown in Fig. 6 A, 48 h 
after transfection, p38A–HEK293-APP cells are characterized 
by a significant increase of both  and  APP C-terminal frag-
ments detected at 10 and 12 kD, respectively, and generated by 
an increased processing of APP (2.82-fold).
To demonstrate that this phenomenon is not caused by the 
increased synthesis of APP (and/or PS2), we measured the lev-
els of these proteins in p38A- and pMock-transfected HEK293-
APP cells by Western blotting. Again, the levels of these proteins 
turned out to be unaffected by the expression of 38A (Fig. 6 B), 
further demonstrating that this ncRNA affects amyloid secretion 
by promoting APP processing by the means of a mechanism medi-
ated by the synthesis of an alternative form of KCNIP4.
Additional evidence that the perturbation of A secretion 
is the consequence of an enhanced APP processing arose from 
an experiment in which SHSY5Y cells were transfected with 
different combinations of plasmids harboring (a) pGal4-APP,   
a plasmid encoding for APP fused to the Gal4 activation do-
main (in this case, when APP is processed, the Gal4 activation 
activates the transcription of a cotransfected Gal4-dependent 
reporter gene); (b) pGal4-Luc, encoding for the Gal4-dependent 
luciferase, thus activated by the processing of Gal4-APP;   
(c) p38A, encoding for 38A transcript driven by its natural pro-
moter; and (d) pRL, encoding for Renilla luminescent protein as 
a normalizer. Results showed that in 38A-overexpressing cells, 
the processing of APP is significantly augmented, as revealed by 
an amplification of luciferase signal consequent to the release of 
the Gal4 activation domain (Fig. 6 C). Again, this demonstrates 
that the transcription of 38A ncRNA leads to a perturbation of 
APP processing that then leads to the increase of A secretion.
Figure 6.  Increased APP processing in 38A-overexpressing 
cells. (A) Quantitative Western blotting analysis of APP 
C-terminal fragments in pMock- and/or p38A-transfected 
cells (P = 0.023, as the averaged result of five experiments). 
Error bars represent SD. (B) Quantitative determination of 
APP and PS2 synthesis in pMock- and/or p38A-transfected 
cells by Western blotting analysis. All of the determinations 
were normalized to -tubulin expression. Error bars repre-
sent SD. (C) Determination of APP processing by pGAL4-
activated luciferase assay: c, pLuc + pRL were transfected; 
pMock, pGal4-APP + pGAL4-Luc + pMock + pRL were trans-
fected; and p38A, pGal4-APP + pGAL4-Luc + p38A + pRL 
were transfected.JCB • VOLUME 193 • NUMBER 5 • 2011   860
Figure  7.  ncRNA  expression  and  alternative 
splicing in AD cases. (A) 38A expression in AD 
cases (orange bars) and nADc individuals (green 
bars) as determined by quantitative real-time RT-
PCR. AD cases 124 and 1,024 have a familiar 
genetic  origin.  The  amplification  product  dis-
sociation curves unambiguously distinguish the 
RNAs of interest by peaks at specific tempera-
tures (insets). Error bars represent SD of three in-
dependent real-time RT-PCR determinations. The 
averaged results are also reported. (B) Real-time 
RT-PCR quantitative detection of KCNIP4 splice 
variant synthesis in AD patients and nADc indi-
viduals. Results are reported as the splice variant 
ratio (KCNIP4 Var IV vs. Var I). Error bars rep-
resent SD of three independent real-time RT-PCR 
determinations. The averaged ratios are also re-
ported. The dissociation curves (insets) show that 
the splice variants of interest are unambiguously 
distinguishable  by  peaks  at  specific  tempera-
tures. DSE, distal sequence element.861 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
Var I (Fig. 7 B). Therefore, these results not only confirm ex vivo 
what was previously demonstrated in vitro but also associate the 
occurrence of this phenomenon with the most common neuro-
degenerative pathology, AD.
Alternative 38A promoter variants exhibit 
peculiar transcriptional properties
To assess the relevance of KCNIP4 alternative splicing in neuro-
degeneration and with the final aim to identify 38A genetic varia-
tions associated with its unusual expression in AD samples, we 
sequenced the 38A genomic regions of 39 cerebral cortex sam-
ples from diseased and nondiseased cases. Results showed that, 
although the transcribed portion of 38A did not harbor major ge-
netic alterations that might support its increased stability, 38A 
promoters contain recurrent genetic variations that could be re-
sponsible for its altered expression activation in AD cases. In 
detail, we isolated and cloned four different promoter variants, 
hereafter referred to as , , , and  (Fig. 8 A and Table S2). 
Considering the  variant as the wild type (wt) and / being the 
canonical wt genotype, we found a significant number of hetero-
zygous genotypes (hereafter referred to as /) in the cerebral 
cortices that we analyzed ( being , , or  alleles). Interest-
ingly, we found that in nADcs, the frequency of / homozygous 
and that of heterozygous genotypes was rather similar (47 and 
53% of the cases, respectively); alternatively, this ratio is altered 
in AD samples in which the / genotype was associated with 
27% of the individuals, whereas the / heterozygous genotype 
was found in 73% of the diseased cases (Fig. 8 B). Although, be-
cause of the restricted number of samples in our collection (n = 
39), the different frequencies of promoter variants are not statisti-
cally significant to derive a detailed genetic determination of the 
impact of different promoters in the disease (
2 = 1.63, g = 1, and 
P = 80%), the genetic data obtained by this screening suggest that 
38A overexpression is not an individual single determinant of the 
disease but rather is part of a multifactorial network of events. 
The transcriptional properties of 38A promoter variants were 
then investigated to identify an allele-specific regulation of tran-
scription that might explain the increased frequency of the het-
erozygous haplotype among AD cases (Table S2). We found that 
the expression of the ncRNA is dependent on the PolIII promoter 
variant that drives its synthesis in a cell type–specific manner, 
leading to functionally active 38A ncRNA (Fig. S4). Altogether, 
these data demonstrate the occurrence of cell type–specific ex-
pression of 38A promoter variants that is compatible with a pos-
sible individual susceptibility to 38A transcriptional stimuli that 
might occur differentially in diseased and control cases.
38A expression is triggered by 
inflammatory stimuli
As the aforementioned findings demonstrate a role of 38A in 
brain function and, possibly, in neurodegeneration associated 
with AD,  we  focused  on  the  investigation  of  possible  bio-
chemical stimuli that may promote 38A transcription in neu-
rodegenerative disorders. Because several studies support the 
hypothesis of a relevant contribution of inflammatory stimuli to 
AD onset (Griffin et al., 1989; McGeer et al., 2006; Wyss-Coray,   
2006), we tested the effect on 38A expression of treatments with 
different proinflammatory molecules in SHSY5Y cells. We found 
that 12 h after treatment, 0.5 ng/ml IL1- strongly up-regulates 
38A expression, whereas the addition of IL1 receptor antago-
nist (IL1ra, a natural inhibitor of IL1- proinflammatory effect) 
prevents the IL1-–dependent increase of 38A transcription, 
demonstrating further the specificity of IL1- action (Fig. 9, 
A and B). We then measured the expression of IL1- recep-
tor by real-time RT-PCR in the same samples. IL1- receptor 
expression was found to be abundant in HeLa and, at a lesser 
extent  in  HEK293  cells,  not  detected  in  SHSY5Y-untreated 
cells, where it was induced by the treatment with the inflam-
matory agent, supporting the effects of IL1- on A process-
ing described in this paper (Fig. 9 C). Next, we repeated the 
induction of 38A expression with IL1- in samples previously 
treated with Diclofenac to test a possible protective effect of a 
nonsteroidal antiinflammatory drug on 38A activation. Under 
these conditions, IL1-–dependent 38A activation was abolished, 
thus demonstrating that the inhibition of the COX-2 (Cyclo-
oxygenase-2)–dependent inflammatory cascade is sufficient to 
prevent IL1-–dependent up-regulation of 38A and its possible 
detrimental consequences (Fig. 9 D). Altogether, these results 
demonstrate that 38A expression is induced by IL1- and that 
the harmful effects of its activation (such as the increased pro-
cessing of A and the impairment of A-type potassium current) 
might be triggered in vivo by this inflammatory stimulus.
Discussion
In this paper, we propose that a newly identified ncRNA mole-
cule transcribed by RNA PolIII, 38A, controls the splicing pro-
cess of a protein-coding gene, KCNIP4, and that this mechanism 
Figure 8.  38A promoter variants analysis. (A) A schematic representa-
tion of 38A promoter genetic variants. (B) Relative frequencies of genetic 
configurations. / genetic configuration versus / genetic configuration 
in AD cases and in nADcs (C).JCB • VOLUME 193 • NUMBER 5 • 2011   862
whereas the heterozygous genetic configurations are more fre-
quently associated with the AD individuals; and (g) the alterna-
tive promoter variants appear to be expressed in a cell type–specific 
manner so that in each cell type, the 38A expression is allele 
specific. This finding suggests that, in specific conditions, indi-
viduals harboring the , , , or  allele might be differentially 
prone to 38A activation. The fact that the activation of 38A and 
of the subsequent cascade of reactions is induced specifically by 
IL1- suggests that the active synthesis of this ncRNA in AD 
cortices may be promoted by a prolonged inflammation that 
would thus anticipate the neurodegenerative manifestations. In 
this context, the present work provides a mechanistic link be-
tween inflammation and AD, supporting the hypothesis that pro-
tracted inflammatory stimuli might contribute to its onset and/or 
maintenance and indicating the possible use of antiinflamma-
tory drugs to prevent AD.
In light of the aforementioned findings, we propose a model 
that is in line with the amyloid hypothesis and proposes a series 
of inflammation-dependent early events that ultimately lead to 
altered amyloid production and to the impairment of a voltage-
dependent current contributing to the excitatory properties to 
neurons (Fig. 10). Although at present it is not clear whether 38A 
is essential for AD onset or is rather part of a pathological condition 
of the brain that occurs in numerous neurodegenerative disorders, 
this model provides a novel way to investigate neurodegenera-
tions and brain function based on an alternative cascade of reac-
tions unexpectedly controlled by a PolIII-transcribed ncRNA.   
of cogene/gene regulation is at the root of a novel PolIII-dependent 
gene expression regulatory mechanism that is of relevant inter-
est in brain physiology and/or pathology. In detail, this work 
demonstrates that (a) after the induction by an inflammatory 
stimulus that promotes its transcription, 38A drives the splicing 
of KCNIP4 pre-mRNA to the synthesis of the alternative pro-
tein Var IV, which differs from the canonical KCNIP4 for its 
N-terminal portion; (b) as a consequence, KCNIP4 loses the 
ability to physically interact with PS2, a component of the   
-secretase complex; (c) this lack of interaction leads to a general 
increase of APP processing and A secretion and to a specific 
alteration of the A x-42/A x-40 ratio, favoring the production 
of the insoluble, more toxic A x-42 species; (d) besides this effect 
on A production, 38A activation and the subsequent synthesis 
of KCNIP4 Var IV lead to the concomitant blockade of the fast 
kinetics of potassium channels with significant inhibition of 
their A-type current (because this current plays an important 
role in the process of LTP associated with brain plasticity and 
memory, this effect is of particular relevance, as it suggests an 
additional detrimental role of 38A with respect to brain physiol-
ogy and thus may account for a novel contribution of 38A to AD 
and to the symptoms associated with neurodegenerative pro-
cesses); (e) 38A is significantly up-regulated in cerebral cortex 
samples of AD individuals in which the concomitant alternative 
splicing of KCNIP4 is observed; (f) the 38A promoter was found 
to occur in four allelic variants, of which the wt homozygous 
/ is more frequently associated with non-AD individuals, 
Figure  9.  Modulation  of  38A  promoter  ac-
tivity by inflammatory and antiinflammatory 
agents. (A) Induction by IL1- treatment and 
recovery  by  IL1ra  of  38A  expression.  The 
results were normalized to the untreated sam-
ples. The effects of different concentrations of 
IL1- treatment on 38A expression are shown 
in  the  inset.  (B)  KCNIP4  splice  variant  shift 
induction and prevention by IL1- and IL1ra, 
respectively. (C) Induction by IL1- treatment 
of  IL1-  receptor  synthesis  in  SHSY5Y  cells. 
HeLa and HEK293 cells were used as posi-
tive  controls.  (D)  Inhibition  of  IL1-–induced 
38A overexpression by Diclofenac treatment. 
Experiments were performed in triplicate and 
repeated  three  times.  Data  are  reported  as 
mean values ± SD. Statistical significance was 
examined using the unpaired Student’s t test.   
*  and  **  indicate  statistical  significance  at   
P < 0.05 and 0.01, respectively.863 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
in the presence of 0.5 mM deoxynucleotide triphosphates and 1 pmol of 
specific 5 end–radiolabeled probe. A mixture providing 50 mM Tris/HCl, 
pH 8, 75 mM KCl, 3 mM MgCl2, 5 mM DTT, 10 U SUPERase IN, and 
200 U Superscript III reverse transcription (Invitrogen) was then added, 
and the reactions were incubated for 1 h at 60°C, precipitated with am-
monium acetate, and gel fractionated. To construct templates for in vitro 
transcription, a 38A fragment was amplified from human genomic DNA and 
cloned into pGEM-Teasy vector (Promega) by using the primers 5-TAATAA-
CAACATATCTGAAAAAGACGC-3  and  5-TTCAGGGTGTCCTGTTGG-
TACC-3. The inserts were then subcloned into pNEB193 vector. The fusion 
38A/7SK DNA fragment was obtained by amplifying the 7SK coding 
region with a primer containing the 38A upstream sequence from 68 to 
27 bp. The hybrid product was cloned into pNEB193 vector.
ChIP
ChIP  and  radiolabeled  PCR  analysis  of  immunoprecipitated  and  input 
DNA  were  performed  as  previously  described  (Wang  et  al.,  2005). 
The following antibodies were used: anti-SNAP43 (a gift from W. Henry, 
Michigan State University, East Lansing, MI; Hirsch et al., 2004), anti-
Brf2/TFIIIB50, and anti-RPC39 (a gift from M. Teichmann, Institut Européen 
de Chimie et Biologie, Bordeaux, France). The following oligonucleotide 
primer pairs were used: 5-AGGTCATCCCTGAGCTGAAC-3 and 5-CCA-
CCTGGTGCTCAGTGTAG-3 for GAPDH; 5-TAATAACAACATATCTGAA-
AAAGACGC-3  and  5-GTGTCTTCTTCAACTTTTTTTATC-3  for  38A; 
and 5-GTACAAAATACGTGACGTAGAAAG-3 and 5-GGTGTTTCGT-
CCTTTCCACAAG-3 for the U6 gene. PCR products were resolved on 6% 
polyacrylamide-1X Tris-borate-EDTA gels, and PCR signals were visualized 
and quantified by Molecular Imager FX (Bio-Rad Laboratories). To estimate   
the specific enrichment of target DNA regions, the ratio of each PolIII-
specific product to that of a PolII-transcribed gene (GAPDH exon 2) in the 
immunoprecipitations was determined after normalization for amplifica-
tion efficiency.
Cell culture, transfection, and luciferase assay
HeLa, SHSY5Y, IMR32, and SKNBE cells were transfected with pEGFP-N1 
constructs using polyethylenimine (PEI; P3143; 1 µg DNA/2.5 µl PEI 10 
mM; Sigma-Aldrich). G418 (Geneticin) was used as a means of selection 
up to 1,000 µg/ml until resistant clones were identified. Clones were then 
preserved in 200 µg/ml G418. The luciferase-based promoter activity assay 
Indeed, although the genetic analysis of 38A alleles in AD 
and controls does not support its role in the disease as a single 
determinant element, the unbalanced frequency of its promoter 
configurations suggests its contribution to the disease in asso-
ciation with other elements. Moreover, the cell type–specific 
regulation of 38A suggests the involvement of still elusive 
PolIII-specific transcription factors whose identification might 
reveal new genes associated with sporadic AD. In this context, 
a detailed investigation of the transcriptional properties of 38A 
promoter variants might allow us to identify possible AD risk 
factors and/or druglike compounds able to decrease the amyloid 
production via 38A transcription inhibition. In conclusion, this   
work provides novel information of particular relevance, as   
(a) it proposes a novel mechanism by which the alternative splic-
ing can be involved in brain pathologies, (b) it proposes a role 
for PolIII-transcribed ncRNAs in orchestrating the regulation 
of a mosaic of alternative protein forms in different tissues or 
cell conditions, and (c) it indicates new specific genomic loci to 
which genetic variations that account for pathological manifes-
tations might be mapped.
Materials and methods
In vitro transcription
Transcription reactions were performed in the presence of 2 µg of template 
DNA and 100 µg HeLa cell nuclear extract supplemented with 50 ng recom-
binant human TATA-binding protein as follows: 5 mM creatine phosphate, 
70 mM KCl, 5 mM MgCl2, 20 mM Tris/HCl, pH 8, 1 mM DTT, 2 µg/ml 
-amanitin, 0.5 mM CTP, ATP, and GTP, 25 µM/10 µCi UTP/-[
32P]UTP, 10 
U SUPERase IN (Invitrogen), and 10% glycerol (vol/vol) for 1 h at 30°C. 
For primer extension analysis, the purified transcripts were resuspended 
Figure 10.  A schematic model of the possible contribu-
tion of the 38A cogene to neurodegeneration.JCB • VOLUME 193 • NUMBER 5 • 2011   864
10  mM  glucose,  and  300  nM  tetrodotoxin;  pH  was  adjusted  to  7.4   
using NaOH. The pipette filling (internal) solution contained 142 mM KCl, 
10 mM Hepes, 2 mM EGTA, 4 mM MgCl2, and 3 mM ATP. The pH was 
adjusted to 7.3 with Tris base. All chemicals were purchased from Sigma-
Aldrich. The external solution was applied to the cell bath by steady perfu-
sion (3 ml/min of gravity flow). The potassium currents were elicited from 
a holding potential of 80 mV by depolarizing voltage pulses ranging 
from 40 to 60 mV at 20-mV increments. The depolarizing voltage pulses 
of 200-ms duration were applied every 5 s. A best fit exponential function 
was used to determine the time constant of the current inactivation.
A detection in SHSY5Y permanently transfected cells
The amount of secreted A x-40 and A x-42 in the media of 38A perma-
nently transfected SHSY5Y cells were evaluated by sandwich ELISA (IBL-
Japan) according to the manufacturer. Because the overexpression of 38A 
did not alter the proliferation rate of SHSY5Y, the equal number of cells 
seeded in 38A-overexpressing and/or control cells remained constant dur-
ing the 48 h of conditioning of the medium by the cells. Notwithstanding, 
the results were normalized either to the cell number as well as to the pro-
tein content of the cell culture showing no variations in the two cells.
Western blot analysis
The proteins were quantified using a commercial protein quantification 
kit (Protein Assay; Bio-Rad Laboratories) according to the manufacturer’s 
instructions. The samples were subsequently analyzed by 10% SDS-PAGE 
and transferred to a nitrocellulose membrane (GE Healthcare). The mem-
branes were initially blocked by an incubation of 2 h in TBS–Tween 20 
(TBST; 50 mM Tris-HCl, 150 mM NaCl, pH 7.5, and 0.05% Tween 20) 
containing 5% nonfat dried milk. The blots were incubated for 1 h with 
the  appropriate  primary  antibodies:  goat  polyclonal  anti–KChIP4  L14   
(sc-46380; 1:100), goat polyclonal anti-KChIP4 (N14; sc-46381; 1:100), 
rabbit polyclonal anti–PS2 H-76 (sc-7861; 1:200; Santa Cruz Biotechnol-
ogy, Inc.), rabbit polyclonal anti–-APP (clone CT695; 1:250; Invitrogen), 
rabbit polyclonal anti–DREAM FL-214 (sc-9142; 1:200; Santa Cruz Bio-
technology, Inc.), and anti–PS1 S182 (1:5,000; P 7854; Sigma-Aldrich).
To  normalize  the  protein  levels  of  KCNIP4,  APP,  and  PS2,  PS1 
Western blot membranes were stripped with Restore Western blot stripping 
reagent (Thermo Fisher Scientific) and then probed with a monoclonal anti-
body against -tubulin (clone B-5-1-2; T 5168; 1:2,000; Sigma-Aldrich). 
APP  C-terminal  fragments  were  analyzed  by  10–18%  Tris-Tricine  SDS-
PAGE followed by Western blotting and immunorivelation with IgGs. All 
primary antibodies were then diluted in 0.1% NaN3 and 1% BSA-TBS. 
After washing with TBST, membranes were incubated with peroxidase-
conjugated secondary antibodies anti–mouse IgGs (1:12,000; A 0168; 
Sigma-Aldrich), anti–rabbit IgGs (A 0545; 1:16,000; Sigma-Aldrich), and 
anti–goat  IgGs  (805–035-180;  Jackson  ImmunoResearch  Laboratories, 
Inc.) for 1 h at RT. After washing, the reactive bands were revealed with 
ECL (GE Healthcare). The densitometric analysis of protein bands was per-
formed taking advantage of the ImageJ software system (National Institutes 
of Health).
Immunoprecipitation
SHSY5Y cells were grown overnight and transiently transfected with p38A 
and/or pMock. 48 h after transfection, the cells were rinsed once with ice-
cold PBS, pH 8, and incubated with 1 mM of chemical cross-linking dithio-
bis-succinimidyl dipropionate (Thermo Fisher Scientific) for 30 min at 25°C. 
The reactions were then quenched in 50 mM Tris-HCl, pH 7.5, for 15 min. 
Cells were then scraped in 50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1% 
Triton, and 1 mM PMSF with the addition of a protease inhibitor cocktail 
(mini-complete; Roche) and passed five times through a 27-gauge needle; 
samples were centrifugated at 11,000 g for 15 min, and the supernatants 
were quantified (Thermo Fisher Scientific) and used for the immunoprecipi-
tation. The solubilized samples were precleared with protein G–conjugated 
agarose (Pharmacia) for 1 h at 4°C, reacted with a primary goat poly-
clonal antibody raised against a peptide mapping within a KCNIP4 inter-
nal region (KChIP4 L-14) overnight followed by incubation with 20 µl of 
protein G–agarose for 1 h at 4°C. After three washing steps in ice-cold 
PBS, pH 8, samples were boiled for 5 min in Laemmli sample buffer supple-
mented by 40 mM DTT and loaded on an SDS-PAGE gel.
KCNIP4 Var IV down-regulation
For KCNIP4 Var IV down-regulation, an engineered microRNA-KCNIP4V4, 
5-TGCTGTATCATTTCAAGCCCTTCCAAGTTTTGGCCACTGACTGACTTG-3,   
was designed against the 5-specific sequence following the BLOCK-iT PolII 
miR RNAi Expression Vector kit guidelines (Invitrogen) and cloned in the 
pCEG vector. Control experiments were performed using either pCEG alone 
(a gift from T. Russo, University of Naples-Federico II, Naples, Italy) was 
performed using the dual luciferase reporter assay system (Promega) ac-
cording to the manufacturer’s protocol. ML-60218 (EMD) was added to the 
medium at the concentration of 20 µM 26 h before the assay.
DNA sequencing
All of the DNA samples were sequenced using the BigDye Terminator DNA 
sequencing  kit  (Applied  Biosystems)  according  to  the  manufacturer’s 
instructions.
Real-time quantitative RT-PCR analysis
Total RNAs were extracted using TRIZOL reagent (Invitrogen), subjected to 
reverse transcription by the Omniscript RT kit (QIAGEN), and measured by 
real-time quantitative RT-PCR using the PE ABI PRISM 7700 Sequence De-
tection System and Sybr green method (PerkinElmer). The sequences of 
38A forward and reverse primers were 5-CTATCAAAATTTCAAGGATAT-
GCATCA-3 and 5-GATGCCTCAAGCTTTGTTTTGC-3. The sequences of 
KCNIP4  (Var  I)  forward  and  reverse  primers  were  5-ATGAAGCTCTT-
GCCCTGCTC-3 and 5-CGGTGGCCATCTCCAGTT-3. The sequences of 
KCNIP4 (Var IV) forward and reverse primers were 5-TGGAACAGTTT-
GGGCTGATTG-3 and 5-CGGTGGCCATCTCCAGTT-3. For endogenous 
control, the expression of the GAPDH gene was examined. The sequences 
for  human  GAPDH  primers  were  5-GAAGGTGAAGGTCGGAGTC-3 
and  5-GAAGATGGTGATGGGATTTC-3.  The  sequences  for  human  5s 
rRNA  primers  were  5-TACGGCCATACCACCCTGAA-3  and  5-GCG-
GTCTCCCATCCAAGTAC-3. The sequences for human 7SK RNA primers 
were 5-AGGACCGGTCTTCGGTCAA-3 and 5-TCATTTGGATGTGTCTG-
CAGTCT-3. The sequences for human c-Myc primers were 5-CGTCTC-
CACACATCAGCATAA-3 and 5-GACACTGTCCAACTTGACCCTCTT-3.
Immunofluorescence detection
SHSY5Y cells were grown overnight on culture slides and then transfected 
with pcr2.1-38A (or pcr2.1 as a control) using PEI. 48 h after transfection, 
the cells were washed in PBS, fixed for 10 min with 10% buffered forma-
line, and blocked for 15 min with 3% BSA in PBS. Cells were subsequently 
incubated with primary antibodies overnight at 4°C in 0.5% BSA in PBS. 
The day after, the cells were labeled with secondary antibodies for 45 min 
in 0.5% BSA/PBS solution. (Only the slides for PS1 and the downstream 
regulatory  element  antagonist  modulator  [DREAM]  after  the  incubation 
with primary and secondary antibody for DREAM were permeabilized for 
5 min with 0.25% Triton X-100 in PBS, blocked for 5 min with 3% BSA in 
PBS, and incubated with antibody for PS1 that recognized the C terminus 
of the protein and with the secondary antibody. Because DREAM and PS1 
were both produced in rabbit, a control without primary antibody for PS1 
was also performed to verify the absence of reaction between intracellular   
DREAM and secondary anti–rabbit rhodamine-TRITC.) Cells were then incu-
bated with DAPI for 5 min and mounted with Mowiol (Invitrogen). Immuno-
stained cells were observed with the appropriate filters on a microscope 
(Axiovert 200 M; Carl Zeiss) with a 40×/0.75 Plan Neofluar objective 
and captured with a camera (Axiocam HR; Carl Zeiss) at the same ad-
justments of laser intensity and photomultiplier sensitivity using AxioVision 
Release 4.8.1 software (Carl Zeiss). Antibodies used were mouse mono-
clonal anti–PS2 H-76 (1:50; sc-7861; Santa Cruz Biotechnology, Inc.), 
rabbit polyclonal anti–KCNIP4 Var IV (1:200; raised against the sequence 
KLLEQFGLIEAGLEC), goat polyclonal anti–KCNIP4-N14 (1:200; sc-46381; 
Santa  Cruz  Biotechnology,  Inc.),  rabbit  polyclonal  anti–DREAM  FL-214 
(1:200; sc-9142; Santa Cruz Biotechnology, Inc.), and rabbit polyclonal 
anti–PS1 S182 (1:100; P 7854; Sigma-Aldrich). Secondary antibodies 
used were anti–goat rhodamine-TRITC (1:200; Jackson ImmunoResearch 
Laboratories, Inc.) for KCNIP4-N14, anti–rabbit rhodamine-TRITC (1:200; 
Jackson ImmunoResearch Laboratories, Inc.) for KCNIP4 Var IV and PS1, 
anti–mouse FITC (1:200; Jackson ImmunoResearch Laboratories, Inc.) for 
PS2, anti–rabbit FITC (1:200; Jackson ImmunoResearch Laboratories, Inc.) 
for DREAM and KCNIP4 Var IV, and anti–mouse rhodamine-TRITC (1:200) 
for PS2 (Jackson ImmunoResearch Laboratories, Inc.)
Detection of fast inactivation of K
+ channels
Currents were measured with a standard whole cell patch clamp technique 
using an EPC-7 amplifier (D-6100; Darmstadt List Medical). Patch pipettes 
were prepared from borosilicate glass capillaries using a P-30 puller (Sut-
ter Instrument). Membrane potential and ionic currents were measured in 
the standard whole cell patch clamp configuration. Ionic currents were re-
corded with a Labmaster D/A, A/D converter driven by pClamp software 
(Axon Instruments). Analysis was performed with pClamp and SigmaPlot 
software (Jandel Scientific). The standard external solution contained 
135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM Hepes, 865 Control of splicing by an RNA polymerase III ncRNA • Massone et al.
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or the pCMMP retroviral GFP vectors. SHSY5Y wt cells were cotransfected 
with a construct expressing 38A (pcr2.1-38A or pcr2.1 as a control) and 
microRNA-KCNIP4V4 (or a scrambled negative microRNA control) with 
microporator (DigitalBio) at 1,400 V, 20 ms, and one pulse. 48 h after 
transfection, RNA extraction and amyloid detection on conditioned media 
were performed. For KCNIP4 Var IV down-regulation, SHSY5Y cells were 
transfected with a construct expressing the KCNIP4 Var IV and KCNIP4-
KIS domain, provided by P. Liang and K. Wang (Neuroscience Research 
Institute, Peking University Health Science Center, Beijing, China).
Statistics
Experiments were performed in triplicate and repeated three times. Data 
are reported as mean values ± SD, and statistical significance was exam-
ined using the unpaired Student’s t test. In the figures, * and ** indicate statis-
tical significance at P < 0.05 and 0.01, respectively.
Human brain samples
Frontal and temporal cortices from AD (clinical history of disease; patho-
logical diagnosis according to the Consortium to Establish a Registry for 
Alzheimer’s Disease criteria) and control cases (AD excluded by clinical 
history  and  by  immunohistochemical  analysis)  derive  from  P.  Gambetti 
(Case Western Reserve University, Cleveland, OH) and C. Hulette and the 
Joseph and Kathleen Bryan Alzheimer’s Disease Research Center (Duke 
University Medical Center, Durham, NC). Patient characteristics are sum-
marized in Table S1.
Online supplemental material
Fig. S1 shows the schematic view and sequences of KCNIP4 alternatively 
spliced protein variants (A) and the schematic view of KCNIP4 alternatively 
spliced RNAs (B). Fig. S2 shows PolIII dependency of 38A-driven alternative 
splicing shift, and Fig. S3 shows that the alternative splicing of KCNIP4 
Var IV plays a key role in the impairment of A processing. Fig. S4 show 
the transcriptional activity and amyloid secretion in SHSY5Y cells overex-
pressing 38A under the control of different 38A promoter variants. Table S1 
shows cerebral cortex samples, and Table S2 shows the relative frequen-
cies of 38A promoter genetic variants in Alzheimer’s-diseased cerebral 
cortices and nADc individuals. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.201011053/DC1.
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